Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 10/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24993310 | 0.84 | P2RX7 (0.41) | CNR1GRM5CYP1A2CYP3A4 | |
| SCHEMBL23015757 | 0.80 | CNR1 (0.45) | CNR1BRD4HPGDNPC1RAB9A | |
| SCHEMBL1760148 | 0.79 | KDM4E (0.41) | HPGD | |
| SCHEMBL29338003 | 0.79 | CD38 (0.47) | CNR1BRD4NPC1RAB9A | |
| SCHEMBL12990143 | 0.79 | MRGPRX4 (0.41) | CYP1A2CYP3A4NPC1RAB9A | |
| SCHEMBL31636273 | 0.78 | ADORA3 (0.42) | CDC7CCNCCDK8 | |
| SCHEMBL19151634 | 0.78 | ADORA3 (0.42) | CDC7CCNCCDK8 | |
| SCHEMBL164543 | 0.76 | CNR1 (0.42) | CNR1BRD4HPGDBAZ2BGRM5 | |
| SCHEMBL13097165 | 0.76 | GRM5 (0.54) | CNR1BRD4HPGDBAZ2BGRM5 | |
| SCHEMBL26986930 | 0.76 | CNR1 (0.42) | CNR1BRD4HPGDCDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | CNR1 453/4885BRD4 2933/4885HPGD 1457/4885 |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | CSF1R, CSF3R, FLT3 | CNR1 398/4885BRD4 795/4885HPGD 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.